Structured Review

Hospira fluconazole
Nanoscale mixed-species biofilm of S. aureus and C. albicans on chip. (A) Fluorescence micrographs of a section of the spot containing mixed-species nanobiofilms stained with FUN-1 and concanavalin A. Staining with FUN-1 demonstrated all viable fungal and bacterial populations (in orange-yellow), and concanavalin A stained only fungal cell walls (in blue). (B to D) Profile of susceptibility of mixed-species biofilms of S. aureus and C. albicans to antibiotics (B), antifungals (C), and combination treatment (D). The data represent dose-response profiles of mixed-species biofilms with respect to ciprofloxacin, vancomycin, tobramycin, and methicillin (B) and to amphotericin B and <t>fluconazole</t> (C) at 50, 5, 0.5, 0.05, and 0.005 μg/ml. (D) Profile of susceptibility to combinations of 25 μg/ml of vancomycin (VANC) with 25, 2.5, 0.25, 0.025, and 0.0025 μg/ml of amphotericin B (AMB) and fluconazole (FLU).
Fluconazole, supplied by Hospira, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluconazole/product/Hospira
Average 90 stars, based on 4 article reviews
Price from $9.99 to $1999.99
fluconazole - by Bioz Stars, 2020-09
90/100 stars

Images

1) Product Images from "nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications"

Article Title: nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications

Journal: mSphere

doi: 10.1128/mSphere.00247-17

Nanoscale mixed-species biofilm of S. aureus and C. albicans on chip. (A) Fluorescence micrographs of a section of the spot containing mixed-species nanobiofilms stained with FUN-1 and concanavalin A. Staining with FUN-1 demonstrated all viable fungal and bacterial populations (in orange-yellow), and concanavalin A stained only fungal cell walls (in blue). (B to D) Profile of susceptibility of mixed-species biofilms of S. aureus and C. albicans to antibiotics (B), antifungals (C), and combination treatment (D). The data represent dose-response profiles of mixed-species biofilms with respect to ciprofloxacin, vancomycin, tobramycin, and methicillin (B) and to amphotericin B and fluconazole (C) at 50, 5, 0.5, 0.05, and 0.005 μg/ml. (D) Profile of susceptibility to combinations of 25 μg/ml of vancomycin (VANC) with 25, 2.5, 0.25, 0.025, and 0.0025 μg/ml of amphotericin B (AMB) and fluconazole (FLU).
Figure Legend Snippet: Nanoscale mixed-species biofilm of S. aureus and C. albicans on chip. (A) Fluorescence micrographs of a section of the spot containing mixed-species nanobiofilms stained with FUN-1 and concanavalin A. Staining with FUN-1 demonstrated all viable fungal and bacterial populations (in orange-yellow), and concanavalin A stained only fungal cell walls (in blue). (B to D) Profile of susceptibility of mixed-species biofilms of S. aureus and C. albicans to antibiotics (B), antifungals (C), and combination treatment (D). The data represent dose-response profiles of mixed-species biofilms with respect to ciprofloxacin, vancomycin, tobramycin, and methicillin (B) and to amphotericin B and fluconazole (C) at 50, 5, 0.5, 0.05, and 0.005 μg/ml. (D) Profile of susceptibility to combinations of 25 μg/ml of vancomycin (VANC) with 25, 2.5, 0.25, 0.025, and 0.0025 μg/ml of amphotericin B (AMB) and fluconazole (FLU).

Techniques Used: Chromatin Immunoprecipitation, Fluorescence, Staining

2) Product Images from "An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva"

Article Title: An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva

Journal: Frontiers in Microbiology

doi: 10.3389/fmicb.2016.00686

Inhibition of biofilm formation in single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) by monotherapy (A) and by antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 0.5, 0.25, 0.125, 0.0625, and 0.03125 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.
Figure Legend Snippet: Inhibition of biofilm formation in single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) by monotherapy (A) and by antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 0.5, 0.25, 0.125, 0.0625, and 0.03125 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.

Techniques Used: Inhibition

Antimicrobial susceptibility patterns of preformed single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) using monotherapy (A) and antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 1, 0.5, 0.25, 0.125, 0.0625 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.
Figure Legend Snippet: Antimicrobial susceptibility patterns of preformed single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) using monotherapy (A) and antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 1, 0.5, 0.25, 0.125, 0.0625 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.

Techniques Used:

3) Product Images from "Azole Heteroresistance in Cryptococcus neoformans: Emergence of Resistant Clones with Chromosomal Disomy in the Mouse Brain during Fluconazole Treatment"

Article Title: Azole Heteroresistance in Cryptococcus neoformans: Emergence of Resistant Clones with Chromosomal Disomy in the Mouse Brain during Fluconazole Treatment

Journal: Antimicrobial Agents and Chemotherapy

doi: 10.1128/AAC.00694-13

(A and B) Treatment of the infected mice with fluconazole (FLC) reduces the fungal burden. The number of CFU in brain tissue of mice infected with NIH38 (LHF, 8 μg/ml) and NIH9 (LHF, 32 μg/ml) and treated with FLC was determined. The data show that the efficacy of FLC treatment may be related to the drug resistance levels of the strains. N.A., not applicable. (C and D) Prolonged treatment with FLC increases the percentage of the FLC-resistant population in brain tissue of mice. The percentage of the FLC-resistant population was monitored from the brain tissue of mice infected with low-LFH (NIH38) and high-LHF (NIH9) strains.
Figure Legend Snippet: (A and B) Treatment of the infected mice with fluconazole (FLC) reduces the fungal burden. The number of CFU in brain tissue of mice infected with NIH38 (LHF, 8 μg/ml) and NIH9 (LHF, 32 μg/ml) and treated with FLC was determined. The data show that the efficacy of FLC treatment may be related to the drug resistance levels of the strains. N.A., not applicable. (C and D) Prolonged treatment with FLC increases the percentage of the FLC-resistant population in brain tissue of mice. The percentage of the FLC-resistant population was monitored from the brain tissue of mice infected with low-LFH (NIH38) and high-LHF (NIH9) strains.

Techniques Used: Infection, Mouse Assay

4) Product Images from "Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans"

Article Title: Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans

Journal: American Journal of Physiology - Heart and Circulatory Physiology

doi: 10.1152/ajpheart.00073.2013

Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during systemic hypoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values
Figure Legend Snippet: Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during systemic hypoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values

Techniques Used:

Forearm vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. * P
Figure Legend Snippet: Forearm vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. * P

Techniques Used:

Trial 1: effects of fluconazole and hypoxia on total FBF and SBF and on FVC and SVC.
Figure Legend Snippet: Trial 1: effects of fluconazole and hypoxia on total FBF and SBF and on FVC and SVC.

Techniques Used:

Skin vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. NS, not significant. * P
Figure Legend Snippet: Skin vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. NS, not significant. * P

Techniques Used:

Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during normoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values are means
Figure Legend Snippet: Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during normoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values are means

Techniques Used:

5) Product Images from "Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development"

Article Title: Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development

Journal: Antimicrobial Agents and Chemotherapy

doi: 10.1128/AAC.01084-18

Inhibition of planktonic growth of 10 C. auris strains by ebselen. Graphs depict dose-response activity of ebselen against the different C. auris strains from the CDC panel. The corresponding MIC values for fluconazole, amphotericin B, and caspofungin are included for comparison purposes (*, provided by the CDC, determined by Etest). Experiments were performed in two independent plates with two duplicate wells per plate. Bars indicate standard errors.
Figure Legend Snippet: Inhibition of planktonic growth of 10 C. auris strains by ebselen. Graphs depict dose-response activity of ebselen against the different C. auris strains from the CDC panel. The corresponding MIC values for fluconazole, amphotericin B, and caspofungin are included for comparison purposes (*, provided by the CDC, determined by Etest). Experiments were performed in two independent plates with two duplicate wells per plate. Bars indicate standard errors.

Techniques Used: Inhibition, Activity Assay

Related Articles

Injection:

Article Title: In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation
Article Snippet: .. A stock solution of fluconazole (Hospira, Lake Forest, IL) prepared in sodium chloride for injection at 2 mg/ml was obtained and stored at 4°C until used. .. Amphotericin B was obtained in solution at 250 μg/ml (Gibco Life Technologies, Grand Island, NY) and stored at −20°C until used.

Article Title: Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development
Article Snippet: .. For these studies, a stock solution of fluconazole (Hospira, Lake Forest, IL) was prepared in sodium chloride for injection at 2 mg/ml and stored at 4°C. .. Amphotericin B was obtained in solution at 250 μg/ml (Gibco Life Technologies, Grand Island, NY) and stored at −20°C.

Article Title: An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva
Article Snippet: .. Drugs A stock solution of fluconazole (Hospira, Lake Forest, IL, USA) prepared in sodium chloride for injection at 2 mg/ml was obtained and stored at 4°C until used. .. Amphotericin B was obtained in solution at 250 μg/ml (Gibco Life Technologies, Grand Island, NY, USA) and stored at -20°C until used.

other:

Article Title: Clinical Features and Magnetic Resonance Imaging Findings in 7 Dogs with Central Nervous System Aspergillosis
Article Snippet: Fluconazole 2 mg/mL, Hospira, Inc., Lake Forest, IL

Article Title: An In Vitro Model for Candida albicans–Streptococcus gordonii Biofilms on Titanium Surfaces
Article Snippet: Antimicrobial Drugs The antibiotics used in this study included fluconazole (Hospira, Lake Forest, IL, USA), amphotericin B (Gibco Life Technologies, Grand Island, NY, USA), caspofungin (Merck & Co., Inc., Whitehouse Station, NJ, USA), and clindamycin (RPI Corp., Prospect, IL, USA).

Flow Cytometry:

Article Title: Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans
Article Snippet: .. Fluconazole (Hospira, Lake Forrest, IL) was reconstituted in normal saline and infused at 0.3 mg/min (∼1 μmol/min, 0.5 ml/min), as at continuous infusion rates of 0.4–1.6 μmol/min (for 5–8 min at various levels), fluconazole has been shown to attenuate flow-mediated dilation ( ) and reduce basal blood flow in the radial artery ( ). l -NMMA (Clinalfa) was reconstituted in normal saline and infused at 5 mg/min (0.5 ml/min) intra-arterially for 10 min, as reported previously ( ). ..

Infection:

Article Title: Azole Heteroresistance in Cryptococcus neoformans: Emergence of Resistant Clones with Chromosomal Disomy in the Mouse Brain during Fluconazole Treatment
Article Snippet: .. Fluconazole used for the treatment of infected mice was purchased from Hospira, Inc. (Lake Forest, IL). ..

Mouse Assay:

Article Title: Azole Heteroresistance in Cryptococcus neoformans: Emergence of Resistant Clones with Chromosomal Disomy in the Mouse Brain during Fluconazole Treatment
Article Snippet: .. Fluconazole used for the treatment of infected mice was purchased from Hospira, Inc. (Lake Forest, IL). ..

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Hospira fluconazole
    Nanoscale mixed-species biofilm of S. aureus and C. albicans on chip. (A) Fluorescence micrographs of a section of the spot containing mixed-species nanobiofilms stained with FUN-1 and concanavalin A. Staining with FUN-1 demonstrated all viable fungal and bacterial populations (in orange-yellow), and concanavalin A stained only fungal cell walls (in blue). (B to D) Profile of susceptibility of mixed-species biofilms of S. aureus and C. albicans to antibiotics (B), antifungals (C), and combination treatment (D). The data represent dose-response profiles of mixed-species biofilms with respect to ciprofloxacin, vancomycin, tobramycin, and methicillin (B) and to amphotericin B and <t>fluconazole</t> (C) at 50, 5, 0.5, 0.05, and 0.005 μg/ml. (D) Profile of susceptibility to combinations of 25 μg/ml of vancomycin (VANC) with 25, 2.5, 0.25, 0.025, and 0.0025 μg/ml of amphotericin B (AMB) and fluconazole (FLU).
    Fluconazole, supplied by Hospira, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluconazole/product/Hospira
    Average 90 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    fluconazole - by Bioz Stars, 2020-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Nanoscale mixed-species biofilm of S. aureus and C. albicans on chip. (A) Fluorescence micrographs of a section of the spot containing mixed-species nanobiofilms stained with FUN-1 and concanavalin A. Staining with FUN-1 demonstrated all viable fungal and bacterial populations (in orange-yellow), and concanavalin A stained only fungal cell walls (in blue). (B to D) Profile of susceptibility of mixed-species biofilms of S. aureus and C. albicans to antibiotics (B), antifungals (C), and combination treatment (D). The data represent dose-response profiles of mixed-species biofilms with respect to ciprofloxacin, vancomycin, tobramycin, and methicillin (B) and to amphotericin B and fluconazole (C) at 50, 5, 0.5, 0.05, and 0.005 μg/ml. (D) Profile of susceptibility to combinations of 25 μg/ml of vancomycin (VANC) with 25, 2.5, 0.25, 0.025, and 0.0025 μg/ml of amphotericin B (AMB) and fluconazole (FLU).

    Journal: mSphere

    Article Title: nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications

    doi: 10.1128/mSphere.00247-17

    Figure Lengend Snippet: Nanoscale mixed-species biofilm of S. aureus and C. albicans on chip. (A) Fluorescence micrographs of a section of the spot containing mixed-species nanobiofilms stained with FUN-1 and concanavalin A. Staining with FUN-1 demonstrated all viable fungal and bacterial populations (in orange-yellow), and concanavalin A stained only fungal cell walls (in blue). (B to D) Profile of susceptibility of mixed-species biofilms of S. aureus and C. albicans to antibiotics (B), antifungals (C), and combination treatment (D). The data represent dose-response profiles of mixed-species biofilms with respect to ciprofloxacin, vancomycin, tobramycin, and methicillin (B) and to amphotericin B and fluconazole (C) at 50, 5, 0.5, 0.05, and 0.005 μg/ml. (D) Profile of susceptibility to combinations of 25 μg/ml of vancomycin (VANC) with 25, 2.5, 0.25, 0.025, and 0.0025 μg/ml of amphotericin B (AMB) and fluconazole (FLU).

    Article Snippet: Another iteration of printing was carried out to deposit 50 nl of amphotericin B (Sigma, MO) and fluconazole (Hospira, IL) at dilutions of 50, 5, 0.5, 0.05, and 0.005 μg/ml.

    Techniques: Chromatin Immunoprecipitation, Fluorescence, Staining

    Inhibition of biofilm formation in single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) by monotherapy (A) and by antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 0.5, 0.25, 0.125, 0.0625, and 0.03125 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.

    Journal: Frontiers in Microbiology

    Article Title: An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva

    doi: 10.3389/fmicb.2016.00686

    Figure Lengend Snippet: Inhibition of biofilm formation in single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) by monotherapy (A) and by antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 0.5, 0.25, 0.125, 0.0625, and 0.03125 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.

    Article Snippet: Drugs A stock solution of fluconazole (Hospira, Lake Forest, IL, USA) prepared in sodium chloride for injection at 2 mg/ml was obtained and stored at 4°C until used.

    Techniques: Inhibition

    Antimicrobial susceptibility patterns of preformed single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) using monotherapy (A) and antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 1, 0.5, 0.25, 0.125, 0.0625 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.

    Journal: Frontiers in Microbiology

    Article Title: An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva

    doi: 10.3389/fmicb.2016.00686

    Figure Lengend Snippet: Antimicrobial susceptibility patterns of preformed single- and dual species C. albicans/S. gordonii biofilms formed in 1:1 v/v RPMI/ THB + 0.02% YE media (upper panels A,B) or BMM synthetic saliva (BMM, lower panels A,B) using monotherapy (A) and antibacterial/antifungal combination therapy (B). Drugs concentrations were as follows: Clindamycin at 100, 10, 1, 0.1, 0.01 μM; Fluconazole at 1, 0.5, 0.25, 0.125, 0.0625 mg/ml; Amphotericin B at 16, 4, 1, 0.25, 0.0625 μg/ml, and Caspofungin at 16, 8, 4, 2, 1 μg/ml.

    Article Snippet: Drugs A stock solution of fluconazole (Hospira, Lake Forest, IL, USA) prepared in sodium chloride for injection at 2 mg/ml was obtained and stored at 4°C until used.

    Techniques:

    (A and B) Treatment of the infected mice with fluconazole (FLC) reduces the fungal burden. The number of CFU in brain tissue of mice infected with NIH38 (LHF, 8 μg/ml) and NIH9 (LHF, 32 μg/ml) and treated with FLC was determined. The data show that the efficacy of FLC treatment may be related to the drug resistance levels of the strains. N.A., not applicable. (C and D) Prolonged treatment with FLC increases the percentage of the FLC-resistant population in brain tissue of mice. The percentage of the FLC-resistant population was monitored from the brain tissue of mice infected with low-LFH (NIH38) and high-LHF (NIH9) strains.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Azole Heteroresistance in Cryptococcus neoformans: Emergence of Resistant Clones with Chromosomal Disomy in the Mouse Brain during Fluconazole Treatment

    doi: 10.1128/AAC.00694-13

    Figure Lengend Snippet: (A and B) Treatment of the infected mice with fluconazole (FLC) reduces the fungal burden. The number of CFU in brain tissue of mice infected with NIH38 (LHF, 8 μg/ml) and NIH9 (LHF, 32 μg/ml) and treated with FLC was determined. The data show that the efficacy of FLC treatment may be related to the drug resistance levels of the strains. N.A., not applicable. (C and D) Prolonged treatment with FLC increases the percentage of the FLC-resistant population in brain tissue of mice. The percentage of the FLC-resistant population was monitored from the brain tissue of mice infected with low-LFH (NIH38) and high-LHF (NIH9) strains.

    Article Snippet: Fluconazole used for the treatment of infected mice was purchased from Hospira, Inc. (Lake Forest, IL).

    Techniques: Infection, Mouse Assay

    Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during systemic hypoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans

    doi: 10.1152/ajpheart.00073.2013

    Figure Lengend Snippet: Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during systemic hypoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values

    Article Snippet: Fluconazole (Hospira, Lake Forrest, IL) was reconstituted in normal saline and infused at 0.3 mg/min (∼1 μmol/min, 0.5 ml/min), as at continuous infusion rates of 0.4–1.6 μmol/min (for 5–8 min at various levels), fluconazole has been shown to attenuate flow-mediated dilation ( ) and reduce basal blood flow in the radial artery ( ). l -NMMA (Clinalfa) was reconstituted in normal saline and infused at 5 mg/min (0.5 ml/min) intra-arterially for 10 min, as reported previously ( ).

    Techniques:

    Forearm vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. * P

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans

    doi: 10.1152/ajpheart.00073.2013

    Figure Lengend Snippet: Forearm vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. * P

    Article Snippet: Fluconazole (Hospira, Lake Forrest, IL) was reconstituted in normal saline and infused at 0.3 mg/min (∼1 μmol/min, 0.5 ml/min), as at continuous infusion rates of 0.4–1.6 μmol/min (for 5–8 min at various levels), fluconazole has been shown to attenuate flow-mediated dilation ( ) and reduce basal blood flow in the radial artery ( ). l -NMMA (Clinalfa) was reconstituted in normal saline and infused at 5 mg/min (0.5 ml/min) intra-arterially for 10 min, as reported previously ( ).

    Techniques:

    Trial 1: effects of fluconazole and hypoxia on total FBF and SBF and on FVC and SVC.

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans

    doi: 10.1152/ajpheart.00073.2013

    Figure Lengend Snippet: Trial 1: effects of fluconazole and hypoxia on total FBF and SBF and on FVC and SVC.

    Article Snippet: Fluconazole (Hospira, Lake Forrest, IL) was reconstituted in normal saline and infused at 0.3 mg/min (∼1 μmol/min, 0.5 ml/min), as at continuous infusion rates of 0.4–1.6 μmol/min (for 5–8 min at various levels), fluconazole has been shown to attenuate flow-mediated dilation ( ) and reduce basal blood flow in the radial artery ( ). l -NMMA (Clinalfa) was reconstituted in normal saline and infused at 5 mg/min (0.5 ml/min) intra-arterially for 10 min, as reported previously ( ).

    Techniques:

    Skin vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. NS, not significant. * P

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans

    doi: 10.1152/ajpheart.00073.2013

    Figure Lengend Snippet: Skin vascular conductance responses to regional drug infusions and hypoxia in trials 1 (fluconazole alone) and 2 (fluconazole + l -NMMA), respectively. Values are means ± SE. NS, not significant. * P

    Article Snippet: Fluconazole (Hospira, Lake Forrest, IL) was reconstituted in normal saline and infused at 0.3 mg/min (∼1 μmol/min, 0.5 ml/min), as at continuous infusion rates of 0.4–1.6 μmol/min (for 5–8 min at various levels), fluconazole has been shown to attenuate flow-mediated dilation ( ) and reduce basal blood flow in the radial artery ( ). l -NMMA (Clinalfa) was reconstituted in normal saline and infused at 5 mg/min (0.5 ml/min) intra-arterially for 10 min, as reported previously ( ).

    Techniques:

    Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during normoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values are means

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Endothelium-derived hyperpolarizing factor contributes to hypoxia-induced skeletal muscle vasodilation in humans

    doi: 10.1152/ajpheart.00073.2013

    Figure Lengend Snippet: Change in forearm vascular conductance in response to infusions of fluconazole alone ( trial 1 ) and fluconazole + l -NMMA ( trial 2 ) during normoxia. Open bars, control (uninfused) forearm; filled bars, experimental (drug-infused) forearm. Values are means

    Article Snippet: Fluconazole (Hospira, Lake Forrest, IL) was reconstituted in normal saline and infused at 0.3 mg/min (∼1 μmol/min, 0.5 ml/min), as at continuous infusion rates of 0.4–1.6 μmol/min (for 5–8 min at various levels), fluconazole has been shown to attenuate flow-mediated dilation ( ) and reduce basal blood flow in the radial artery ( ). l -NMMA (Clinalfa) was reconstituted in normal saline and infused at 5 mg/min (0.5 ml/min) intra-arterially for 10 min, as reported previously ( ).

    Techniques: